AMAG Pharmaceuticals (NASDAQ: AMAG) and Cambrex (NYSE:CBM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability.
Earnings & Valuation
This table compares AMAG Pharmaceuticals and Cambrex’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|AMAG Pharmaceuticals||$532.09 million||0.96||-$2.48 million||($6.08)||-2.37|
|Cambrex||$490.64 million||3.32||$81.67 million||$3.05||16.28|
Volatility and Risk
AMAG Pharmaceuticals has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Cambrex has a beta of 2.26, suggesting that its share price is 126% more volatile than the S&P 500.
This is a breakdown of current ratings and recommmendations for AMAG Pharmaceuticals and Cambrex, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
AMAG Pharmaceuticals presently has a consensus target price of $23.58, indicating a potential upside of 63.77%. Cambrex has a consensus target price of $62.33, indicating a potential upside of 25.55%. Given AMAG Pharmaceuticals’ higher probable upside, equities analysts plainly believe AMAG Pharmaceuticals is more favorable than Cambrex.
This table compares AMAG Pharmaceuticals and Cambrex’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Cambrex beats AMAG Pharmaceuticals on 8 of the 10 factors compared between the two stocks.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc., Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l. Its products consist of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It delivers services, such as custom organic synthesis and process development; current good manufacturing practices (cGMP) manufacturing of API and intermediates from grams to hundreds of kilograms; cGMP analytical services; controlled substance research and development (R&D) and manufacture, Schedule II-V, and contract research. It has API R&D and cGMP facilities in the United States and Europe. It supplies over 90 generic APIs.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.